ZERO WORLD RESEARCHアミノ酸・有機酸の学術文献データベース

Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors.

The Journal of clinical investigation2022Hajji N, Hajji N, Garcia-Revilla J, et al.
研究デザインその他の原著論文
対象ヒト

記録の確認項目

研究デザイン
その他の原著論文
対象
ヒト
出版年
2022
出典
doi.org
抄録の表示
表示あり
出版状態
有効な記録
状態確認日
2026/08/17
収集日
2026/08/13
鮮度
確認期限内
確認段階
自動処理
記録状態
公開

抄録

New approaches for the management of glioblastoma (GBM) are an urgent and unmet clinical need. Here, we illustrate that the efficacy of radiotherapy for GBM is strikingly potentiated by concomitant therapy with the arginine-depleting agent ADI-PEG20 in a non-arginine-auxotrophic cellular background (argininosuccinate synthetase 1 positive). Moreover, this combination led to durable and complete radiological and pathological response, with extended disease-free survival in an orthotopic immune-competent model of GBM, with no significant toxicity. ADI-PEG20 not only enhanced the cellular sensitivity of argininosuccinate synthetase 1-positive GBM to ionizing radiation by elevated production of nitric oxide (˙NO) and hence generation of cytotoxic peroxynitrites, but also promoted glioma-associated macrophage/microglial infiltration into tumors and turned their classical antiinflammatory (protumor) phenotype into a proinflammatory (antitumor) phenotype. Our results provide an effective, well-tolerated, and simple strategy to improve GBM treatment that merits consideration for early evaluation in clinical trials.

MeSH

Antineoplastic AgentsArginineArgininosuccinate SynthaseCell Line, TumorGlioblastomaHumansHydrolasesMicrogliaPolyethylene Glycols

DOI 10.1172/jci142137

PMID 35113813

原文・出典を見る →